Sio Gene Therapies, formerly known as Axovant, is a clinical-stage company with a singular focus on pushing the boundaries of gene therapy to develop treatments for debilitating neurodegenerative diseases, including GM1 gangliosidosis, Tay-Sachs/Sandhoff disease, and Parkinson’s disease.
Sio is leveraging its foundational scientific expertise built on decades of research, extensive collaborations with leading gene therapy institutes, and a flexible vector platform to liberate patients with debilitating diseases through the transformational power of gene therapies.
Our mission is simple:
To combine cutting-edge science with bold imagination to develop genetic medicines that aim to radically improve the lives of patients. We are working tirelessly to advance our rare fatal pediatric and adult neurodegenerative programs through clinical development so that patients can access the therapies they need.
Our team is made up of leading scientific and gene therapy experts with decades of experience in all stages of drug development and commercialization. Our leaders are passionate about treating life-limiting neurodegenerative diseases on behalf of patients and their families.
Board of Directors
Frank Torti, MD
Atul Pande, MD
Eric Venker, MD, PharmD
Pavan Cheruvu, MD
Kristiina Vuori, MD, Ph.D.
Guangping Gao, Ph.D.
Sio Gene Therapies believes that patients deserve long-lasting, transformative therapies, not just incremental improvements. We see the potential in harnessing the power of gene therapies to deliver better options for patients and believe that collaborations with other leaders in the field will get us there faster. We look for partners who share our same vision and are driven by the same urgency to deliver new gene therapies to patients. If you are interested in working with us, please contact us at firstname.lastname@example.org.
Sio is proud to partner with the following organizations to accelerate the development of our transformative gene therapies: